At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CVAC CureVac B.V.
Pre-Market Trading 04-09 06:05:28 EDT
2.72
+0.07
+2.64%
盘前2.77
+0.05+1.84%
05:47 EDT
| High2.89 | Low2.66 | Vol589.68K |
| Open2.82 | D1 Closing2.65 | Amplitude8.87% |
| Mkt Cap610.13M | Tradable Cap336.04M | Total Shares224.31M |
| T/O1.62M | T/O Rate0.48% | Tradable Shares123.54M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
ACCESS Newswire · 04-08 11:25
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy
MT Newswires Live · 04-07 11:54
CureVac Gets U.S. FDA Ind Clearance to Initiate Phase 1 Clinical Trial for Novel Mrna-Based Precision Immunotherapy in Sqnsclc
THOMSON REUTERS · 04-07 11:19
CureVac Nv - Patient Treatment Anticipated to Start in Second Half of 2025
THOMSON REUTERS · 04-07 11:19
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
ACCESS Newswire · 04-07 11:15
Is CureVac (CVAC) the Best German Stock to Buy According to Hedge Funds?
Insider Monkey · 04-02
CureVac (CVAC) Gets a Hold from Leerink Partners
TIPRANKS · 03-31
BUZZ-U.S. STOCKS ON THE MOVE-GameStop, Oxford Industries, Wolfspeed
Reuters · 03-28
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Dow Jones · 03-28
U.S.-Listed Shares of CureVac Rise 15.3% After Co's Mrna Patent Upheld by European Patent Office
THOMSON REUTERS · 03-28
U.S.-Listed Shares of CureVac Rise 16% Premarket After Co's Mrna Patent Upheld by European Patent Office
THOMSON REUTERS · 03-28
BUZZ-U.S. STOCKS ON THE MOVE -CureVac, gold miners, Rocket Lab
Reuters · 03-28
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July
MT Newswires Live · 03-28
CureVac says European Patent Office dismissed BioNTech opposition
TIPRANKS · 03-28
BUZZ-CureVac rises on COVID vaccine patent decision
Reuters · 03-28
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
ACCESS Newswire · 03-27
BRIEF-Curevac Receives Positive Validity Decision From European Patent Office In Litigation Against Biontech SE
Reuters · 03-27
Eqs-News: CureVac Receives Positive Validity Decision From European Patent Office in Litigation Against BioNTech Se
THOMSON REUTERS · 03-27
CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31%
Simply Wall St. · 03-10
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
ACCESS Newswire · 02-18
Introduction
Company Name.
CureVac B.V.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App